L-type calcium channel blocker that displays antihypertensive properties. Inhibits Ca2+-induced contractions in depolarized rat aorta (IC50 = 1.9 nM) and displays vasoprotective effects in cardiovascular disease. Inhibits proliferation of human vascular smooth muscle cells and epidermoid carcinoma A431 cells (IC50 = 25 μM).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 567.05. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.76 mL||8.82 mL||17.64 mL|
|5 mM||0.35 mL||1.76 mL||3.53 mL|
|10 mM||0.18 mL||0.88 mL||1.76 mL|
|50 mM||0.04 mL||0.18 mL||0.35 mL|
References are publications that support the biological activity of the product.
Burges et al (1987) Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors. J.Cardiovasc.Pharmacol. 9 110 PMID: 2434785
Yoshida et al (2003) Antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells. Eur.J.Pharmacol. 472 23 PMID: 12860469
Toba et al (2005) Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the NG-nitro-L-arginine methyl ester-induced hype Hypertens.Res. 28 689 PMID: 16392774
If you know of a relevant reference for Amlodipine besylate, please let us know.
View Related Products by Product Action
Keywords: Amlodipine besylate, Amlodipine besylate supplier, Ca2+, channel, blockers, L-type, Calcium, CaV, Channels, L-Type, voltage-gated, voltage-dependent, Norvasc, Voltage-gated, 2571, Tocris Bioscience
2 Citations for Amlodipine besylate
Citations are publications that use Tocris products. Selected citations for Amlodipine besylate include:
Sharma et al (2016) Suppression of protective responses upon activation of L-type voltage gated calcium channel in macrophages during mycobacterium bovis BCG infection PLoS One 11 e0163845 PMID: 27723836
Zhong et al (2014) Serotonin 5-HT3 receptor-mediated vomiting occurs via the activation of Ca2+/CaMKII-dependent ERK1/2 signaling in the least shrew (Cryptotis parva). PLoS One 9 e104718 PMID: 25121483
Do you know of a great paper that uses Amlodipine besylate from Tocris? Please let us know.
Reviews for Amlodipine besylate
Average Rating: 5 (Based on 1 Review.)
Have you used Amlodipine besylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
L-type Ca2+ current was analysed by patch clamp in guinea pig ventricular cardiomyocytes before and after amlodipine (10 µM) superfusion. Amlodipine blocked calcium current density.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.